Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.

After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

The NHS says it already offers some CAR-T therapies and is consulting on "potential future treatments". Only this week, the National Institute for Health and Care Excellence has recommended the use of ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

[80] Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation to bone, spinal cord compression and hypercalcemia.

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases ... at high risk for fracture, as well ...